LGALS9 and primary cutaneous T-cell non-Hodgkin lymphoma: Human recombinant galectin-9 proteins have demonstrated robust anti-cancer activities in different models, such as in cutaneous T cell lymphoma (CTCL) [140] and in a model of chronic myelogenous leukemia [141].